<DOC>
	<DOCNO>NCT00097084</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The purpose study test whether insulin detemir safe least effective alternative insulin glargine control blood glucose basal/bolus therapy patient type 2 diabetes .</brief_summary>
	<brief_title>Comparison Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes least 12 month Treated oral antidiabetic drug insulin regimen without oral antidiabetic drug BMI maximum 40 kg/m2 HbA1c great equal 7.0 % less equal 11.0 % Proliferative retinopathy maculopathy Recurrent major hypoglycaemia Impaired hepatic renal function Cardiac problem uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>